黛力新联合埃索美拉唑、莫沙必利在慢性胃炎治疗中的疗效观察

发布时间：2018-04-25 17:26

本文选题：慢性胃炎 + 胃肠症状分级评估量表　；参考：《山东大学》2014年硕士论文

【摘要】：研究目的：观察黛力新联合埃索美拉唑、莫沙必利在慢性胃炎治疗(chronic gastritis, CG)中的疗效。研究方法：选择在2012年9月至2014年1月期间在山东大学附属济南市中心医院消化内科门诊及入院治疗的符合入组标准的64例慢性胃炎(CG)患者,其中男性患者30例,女性患者34例,患者的年龄为45～67岁,平均年龄为58岁。64例患者被随机分为试验组和对照组两组。试验组：男性患者共14例,女性患者共18例。对照组：男性患者共16例,女性患者共16例。通过统计分析,患者的性别和年龄组成在试验组和对照组之间无显著差异(P0.05)。试验组患者给予氟哌噻吨美利曲辛片(黛力新,丹麦灵北制药有限公司,10.5mg/片),每日2次(早、中午),每次10.5mg；埃索美拉唑镁肠溶片(耐信,阿斯利康制药有限公司,20mg/片),每日2次(早、晚),每次20mg；枸橼酸莫沙必利胶囊(美唯宁,上海信谊药厂有限公司,5mg/片),每日3次,每次10mg；对照组患者给予埃索美拉唑镁肠溶片,每日2次(早、晚),每次20mg；枸橼酸莫沙必利片,每日3次,每次10mg治疗。疗程均为4周,患者在治疗期间被禁止食用刺激性食物及其他可能影响试验的药物。试验开始前和4周后,两组患者分别行GSRS-C、HAD、EQ-5D评估并记录评分。所有患者在整个试验过程中如出现不良反应会被详细的予以记录。应用SPSS19.0软件分析整个试验过程中的数据资料,计量资料通过均数±标准差(x±s)的形式来表示,差异有显著性的标准为P0.05。研究结果： 1.两组治疗前后GSRS-C评分比较试验组患者治疗前的GSRS-C评分为21.62±4.37,治疗后该评分为7.43±3.52；对照组患者治疗前的GSRS-C评分为23.43±5.46,治疗后该评分为14.13±2.51。治疗后试验组与对照组患者的GSRS-C评分与治疗前相比,均有明显下降(P0.05)；与对照组相比,试验组患者治疗后的GSRS-C评分较治疗前下降更明显(P0.05)。两组治疗后症状疗效相比,试验组为93.75%,对照组为78.13%,试验组较对照组明显升高(P0.05)。 2.两组治疗前后HAD评分北较试验组患者治疗前的HAD (A)评分为12.14±4.30,治疗后该评分为4.43±2.62；试验组患者治疗前的HAD (D)评分为15.74±3.20,治疗后该评分为6.36±3.81；对照组患者治疗前的HAD (A)评分为12.52±4.76,治疗后该评分为8.34±3.61；对照组患者治疗前的HAD (D)评分为15.25±2.85,治疗后该评分为10.41±4.18。治疗后试验组与对照组患者的HAD评分与治疗前相比,均有明显下降(P0.05)；与对照组相比,试验组患者治疗后的HAD评分较治疗前下降更明显(P0.05)。 3.两组治疗前后EQ-5D评分比较试验组患者治疗前的EQ-VAS评分为67.35±3.36,治疗后该评分为87.53±3.74；试验组患者治疗前的EQ-5D评分为0.552±0.019,治疗后该评分为0.804±0.021；对照组患者治疗前的EQ-VAS评分为66.43±4.31,治疗后该评分为76.34±3.61；对照组患者治疗前的EQ-5D评分为0.560±0.015,治疗后该评分为0.708±0.022。治疗后试验组与对照组患者的EQ-VAS、EQ-5D评分与治疗前相比,均有明显上升(P0.05)；与对照组相比,试验组患者治疗后的HAD评分上升较治疗前更明显(P0.05)。研究结论： 1.本研究显示,埃索美拉唑、莫沙必利常规治疗能减轻慢性胃炎患者的胃肠道症状,联合黛力新治疗后,胃肠道症状和焦虑抑郁症状改善更为明显。 2.对慢性胃炎伴有精神障碍的患者进行黛力新联合常规治疗,能获得显著疗效,且不良反应少,耐受性好。
[Abstract]:The purpose of the study is:
Objective To observe the efficacy of Deanxit combined with esomeprazole and mosapride in the treatment of chronic gastritis (chronic gastritis, CG).
Research methods:
From September 2012 to January 2014, 64 patients with chronic gastritis (CG) in the Department of Gastroenterology, affiliated to the Ji'nan Central Hospital Affiliated to Shandong University, were treated in the Department of Gastroenterology and hospitalization. There were 30 male patients, 34 female patients, 45~67 years old and 58 year old.64 patients were randomly divided into experimental group and the test group. The control group two groups. In the experimental group, there were 14 male patients and 18 female patients. There were 16 male patients and 16 female patients in the control group. There were no significant differences between the test group and the control group (P0.05) by statistical analysis (P0.05). The patients in the test group were given Flupentixol and Melitracen Tablets (Dai Lixin, Danish Danish North). Pharmaceutical Co., Ltd., 10.5mg/ tablet), 2 times a day (early, noon), each time 10.5mg; Esomeprazole Magnesium Enteric-coated Tablets (faith, AstraZeneca Pharmaceutical Co., 20mg/), 2 times a day (early, late), each time 20mg; citrate mosapride capsule (Mei Wei Ning, Hisense Company Limited, 5mg/ tablets), 3 times a day, each time 10mg; control group of patients. Esomeprazole Magnesium Enteric-coated Tablets, 2 times a day (early, late), each time 20mg, Mosapride Citrate Tablets, 3 times a day, each time 10mg treatment. The course of treatment was 4 weeks. The patients were banned from eating stimulant food and other drugs that may affect the test during the treatment. Before and after the trial, the two groups were evaluated by GSRS-C, HAD, and EQ-5D, respectively. All patients were recorded in detail during the whole test. The SPSS19.0 software was used to analyze the data in the whole test process, and the measurement data were expressed in the form of mean standard deviation (x + s), and the standard of significant difference was P0.05.
The results of the study:
Comparison of GSRS-C scores in 1. and two groups before and after treatment
The GSRS-C score of the patients in the test group was 21.62 + 4.37 before treatment, and the score was 7.43 + 3.52 after treatment, and the GSRS-C score of the control group was 23.43 + 5.46 before treatment. The GSRS-C score of the test group and the control group after the treatment was significantly lower than that before the treatment (P0.05). Compared with the control group, the test was significantly lower than that of the control group. After treatment, the GSRS-C score of the group was more obvious than that before the treatment (P0.05). Compared with the two groups, the experimental group was 93.75%, the control group was 78.13%, and the experimental group was significantly higher than the control group (P0.05).
2. the HAD score was compared to the two groups before and after treatment
The HAD (A) score of the patients in the test group was 12.14 + 4.30 before treatment, and the score was 4.43 + 2.62 after treatment; the HAD (D) score of the test group was 15.74 + 3.20 before treatment, and the score was 6.36 + 3.81 after treatment, and the HAD (A) score of the control group was 12.52 + 4.76 before treatment, and the score was 8.34 + 3.61 after treatment, and the control group was HAD before treatment. D) the score was 15.25 + 2.85. The HAD score of the test group and the control group after treatment was significantly lower than that of the control group (P0.05) after the treatment of 10.41 + 4.18.. Compared with the control group, the HAD score of the patients in the test group was more obvious than that before the treatment (P0.05).
Comparison of EQ-5D scores in 3. and two groups before and after treatment
The EQ-VAS score of the patients in the test group was 67.35 + 3.36 before treatment, and the score was 87.53 + 3.74 after treatment. The EQ-5D score of the experimental group was 0.552 + 0.019 before treatment, and the score was 0.804 + 0.021 after treatment, and the EQ-VAS score of the control group was 66.43 + 4.31 before treatment, and the score was 76.34 + 3.61 after treatment, and the control group was EQ-5 before treatment. The score of D was 0.560 + 0.015. After treatment, the score was EQ-VAS in the test group and the control group after 0.708 + 0.022. treatment. The EQ-5D score of the test group was significantly higher than that before the treatment (P0.05). Compared with the control group, the HAD score of the patients in the test group rose more obviously than that before the treatment (P0.05).
The conclusions are as follows:
1. the study showed that the routine treatment of esomeprazole and Mosapride could relieve the gastrointestinal symptoms in patients with chronic gastritis. After the combined treatment of Deanxit, the symptoms of gastrointestinal tract and the improvement of anxiety and depression were more obvious.
2. the treatment of Deanxit combined with conventional treatment for patients with chronic gastritis and mental disorders can achieve significant curative effect, with fewer adverse reactions and good tolerance.

【学位授予单位】：山东大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R573.3

【参考文献】